Urokinase-type plasminogen activator

Specifically cleaves the zymogen plasminogen to form the active enzyme plasmin.

Quebec platelet disorder

QPD

An autosomal dominant bleeding disorder due to a gain-of-function defect in fibrinolysis. Although affected individuals do not exhibit systemic fibrinolysis, they show delayed onset bleeding after challenge, such as surgery. The hallmark of the disorder is markedly increased PLAU levels within platelets, which causes intraplatelet plasmin generation and secondary degradation of alpha-granule proteins.

None

The disease is caused by variants affecting the gene represented in this entry.

Phosphorylation of Ser-158 and Ser-323 abolishes proadhesive ability but does not interfere with receptor binding.

Produced as an inactive single-chain protein (pro-uPA or sc-uPA), is processed into the active disulfide-linked two-chain form of PLAU/uPA by a proteolytic event mediated, at least, by TMPRSS4.

Belongs to the peptidase S1 family.

Expressed in the prostate gland and prostate cancers.

• Secreted

Urokinase-type plasminogen activator, U-plasminogen activator, uPA, PLAU

• entrezGene:5328
• omim:191840
• swissprot:P00749

Proteins

Oncology

48507Da